Toronto-Based Transition Therapeutics Offers Private Placement
Transition Therapeutics Inc. has entered into a $21.7 million private placement with investors. Under terms of the deal, the investors, which include Oracle Investment Management, members of Transition's board, management and other shareholders, will purchase 2,625,298 units of the company at a price of $4.19 per share.The private placement is expected to close on or about August 15, 2013. Based in Toronto, Transition Therapeutics is a biopharmaceutical company. Update: The company was previously backed by Canadian venture capital firms.
2 August 2013•3 mins read
